Trial Profile
An Open-label, Randomized, 2-treatment, 2-period, Crossover Study to Evaluate the Effect of Probenecid on the Pharmacokinetics of Pexidartinib in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary) ; Probenecid
- Indications Breast cancer; Colorectal cancer; Gastrointestinal stromal tumours; Glioblastoma; Malignant melanoma; Pancreatic cancer; Peripheral nervous system diseases; Pigmented villonodular synovitis; Prostate cancer; Sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 20 Oct 2022 Results published in the Clinical Pharmacokinetics
- 05 May 2017 New trial record